Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Despite advances in healthcare, bacterial pathogens remain a severe global health threat, exacerbated by rising antibiotic resistance. Lower respiratory tract infections, with their high death toll, are of particular concern. Accurately replicating host-pathogen interactions in laboratory models is crucial for understanding these diseases and evaluating new therapies. In this communication, we briefly present existing in vivo models for cystic fibrosis and their limitations in replicating human respiratory infections. We then present a novel, 3D-printed, cytocompatible microfluidic lung-on-a-chip device, designed to simulate the human lung environment, and with possible use in recapitulating general infectious diseases.Our device enables the colonisation of fully differentiated lung epithelia at an air-liquid interface with Pseudomonas aeruginosa, a key pathogen in many severe infections. By incorporating dynamic flow, we replicate the clearance of bacterial toxins and planktonic cells, simulating both acute and chronic infections. This platform supports real-time monitoring of therapeutic interventions, mimics repeated drug administrations as in clinical settings, and facilitates the analysis of colony-forming units and cytokine secretion over time. Our findings indicate that this lung-on-a-chip device has significant potential for advancing infectious disease research, in optimizing treatment strategies against infections and in developing novel treatments.

Download full-text PDF

Source
http://dx.doi.org/10.1007/5584_2024_829DOI Listing

Publication Analysis

Top Keywords

lung-on-a-chip device
8
infections
6
establishment 3d-printed
4
3d-printed tissue-on-a-chip
4
tissue-on-a-chip model
4
model live
4
live imaging
4
imaging bacterial
4
bacterial infections
4
infections despite
4

Similar Publications

Models of Surfactant Replacement Therapy in Neonatal Lungs.

J Biomech Eng

September 2025

Department of Biomedical Engineering, The University of Akron, 244 Sumner Street Akron, OH 44325.

The lungs play a critical role in gas exchange and overall respiratory functions, relying on a delicate balance of pulmonary mechanics and surfactant homeostasis. Surfactant replacement therapy (SRT) is a life-saving intervention for conditions such as neonatal respiratory distress syndrome (NRDS), where surfactant deficiency impairs alveolar stability and normal gas exchange. To improve treatment strategies of lung disorders such as NRDS, researchers have developed a variety of computational, benchtop, and animal models to investigate surfactant transport and drug delivery in the lungs.

View Article and Find Full Text PDF

In vitro biomimetic models for respiratory diseases: progress in lung organoids and lung-on-a-chip.

Stem Cell Res Ther

July 2025

Institute of Orthopedics, The Fourth Medical Center of Chinese PLA General Hospital, Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma & War Injuries PLA, No. 51 Fucheng Road, Beijing, 100048, People's Republic of China.

Respiratory diseases pose a growing global public health challenge due to their rising incidence and mortality. Conventional cellular and animal models fall short in replicating the complex three-dimensional (3D) microenvironments of the lung and are limited by species differences, restricting their clinical relevance. Emerging technologies, such as lung organoids (LOs) and lung-on-a-chip (LOC), combine stem cell differentiation, microfluidic systems, and biomechanical cues to create advanced in vitro models that address these limitations.

View Article and Find Full Text PDF

Lung disease due to non-tuberculous mycobacteria (NTM) is rising in incidence. Although both two-dimensional cell culture and animal models exist for NTM infections, a major knowledge gap is the early responses of human alveolar and innate immune cells to NTM within the human alveolar microenvironment. Here, we describe the development of a humanized, three-dimensional, alveolus lung-on-a-chip (ALoC) model of Mycobacterium fortuitum lung infection that incorporates only primary human cells, such as pulmonary vascular endothelial cells, in a vascular channel, and type I and II alveolar cells and monocyte-derived macrophages in an alveolar channel along an air-liquid interface.

View Article and Find Full Text PDF

Conventional in vitro and preclinical animal models often fail to accurately replicate the complexity of human diseases, limiting the success of translational studies and contributing to the low success rate of clinical trials (Ingber 2016). In response, research has increasingly focused on organ-on-chip technology, which better mimics human tissue interfaces and organ functionality. In this study, we describe the fabrication of a novel biomembrane made of porous silicon (PSi) for use in organ-on-chip systems.

View Article and Find Full Text PDF

Dynamics of nanoparticles in a 3D breathing lung-on-a-chip.

Drug Deliv Transl Res

April 2025

Queensland Micro- and Nanotechnology Centre, Nathan Campus, Griffith University, 170 Kessels Road, Brisbane, QLD, 4111, Australia.

The"Breathing Lung-on-a-Chip,"a novel microfluidic device featuring a stretchable membrane, replicates the natural expansion and contraction of the human lung. It provides a more realistic in-vitro platform to study respiratory diseases, particle deposition, and drug delivery mechanisms. This device enables investigations into the effects of inhaled nanoparticles (NPs) on lung tissue and supports the development of advanced inhalation therapies.

View Article and Find Full Text PDF